Clinical trial
Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable…
NCT00079352 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00079352 |
|---|---|
| Title | Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors |
| Official title | A Phase I Study of Flavopiridol in Combination With Gemcitabine and Irinotecan in Patients With Metastatic Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | alvocidib, gemcitabine hydrochloride, irinotecan hydrochloride |
| Enrollment | 24 |
| Start date | Apr 1, 2004 |
| Primary completion | Oct 1, 2007 |
| First posted | Mar 10, 2004 |
| Last update posted | Jan 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: